AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27312565 — intervention group
Group type: COMPARATOR
Intervention: Carbonated water (control)
Number of subjects: 80
Study 25811847 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS + CHX
Number of subjects: 100
Study 25811847 — intervention group
Group type: EXPERIMENTAL
Intervention: QS + CHX
Number of subjects: 100
Study 25811847 — intervention group
Group type: COMPARATOR
Intervention: FMS
Number of subjects: 100
Study 23580602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrokinetically modified water (EMW)
Number of subjects: 40
Study 21934569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner therapy (PDPT)
Number of subjects: 75
Study 21934569 — intervention group
Group type: EXPERIMENTAL
Intervention: inSPOT
Number of subjects: 75
Study 21934569 — intervention group
Group type: EXPERIMENTAL
Intervention: inSPOT/PDPT
Number of subjects: 75
Study 21934569 — intervention group
Group type: COMPARATOR
Intervention: Standard partner management
Number of subjects: 75
Study 19728711 — intervention group
Group type: EXPERIMENTAL
Intervention: Porridge with 4 g of beta-glucan
Number of subjects: 0
Study 19728711 — intervention group
Group type: EXPERIMENTAL
Intervention: Granola with 4 g of beta-glucan
Number of subjects: 0
Study 19728711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 4 g of beta-glucan
Number of subjects: 0
Study 19728711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta with 4 g of beta-glucan
Number of subjects: 0
Study 19728711 — intervention group
Group type: COMPARATOR
Intervention: Control products with low beta-glucan content
Number of subjects: 0
Study 17911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban therapy (N = 390; mean dose of 1.9 microg/kg/min for a mean 6 days)
Number of subjects: 488
Study 17911186 — intervention group
Group type: COMPARATOR
Intervention: Historical control therapy (N = 98)
Number of subjects: 488
Study 17911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban therapy
Number of subjects: 488
Study 15819461 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine capsule
Number of subjects: 12
Study 15819461 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine tablet
Number of subjects: 12
Study 15819461 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of quinine
Number of subjects: 12
Study 11688589 — intervention group
Group type: EXPERIMENTAL
Intervention: FIS (Flexion in Standing)
Number of subjects: 100
Study 11688589 — intervention group
Group type: EXPERIMENTAL
Intervention: EIS (Extension in Standing)
Number of subjects: 100
Study 11688589 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL (Flexion in Lying)
Number of subjects: 100
Study 11688589 — intervention group
Group type: EXPERIMENTAL
Intervention: EIL (Extension in Lying)
Number of subjects: 100
Study 11688589 — intervention group
Group type: COMPARATOR
Intervention: All exercise groups (FIS, EIS, FIL, EIL)
Number of subjects: 100
Study 9190868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg/2 min i.v.
Number of subjects: 38
Study 1539815 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.2 mg/h) + epidural bupivacaine (10 mg/h)
Number of subjects: 24
Study 1539815 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (0.2 mg/h) alone
Number of subjects: 24
Study 4002781 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine (M) 240 mg oral dose during dialysis (A)
Number of subjects: 6
Study 4002781 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine (M) 240 mg oral dose after dialysis (B)
Number of subjects: 6
Study 30844983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral resistance training (BIL, n = 13)
Number of subjects: 33
Study 30844983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (UNI, n = 10)
Number of subjects: 33
Study 30844983 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (COM, n = 10)
Number of subjects: 33
Study 30656180 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg/day
Number of subjects: 69
Study 30656180 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg/day in patients without pes cavus
Number of subjects: 69
Study 30656180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 28763412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-Band Wire (TBW) fixation
Number of subjects: 67
Study 28763412 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation
Number of subjects: 67
Study 26562376 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-layer soft silicone foam dressing applied to each heel
Number of subjects: 150
Study 26562376 — intervention group
Group type: COMPARATOR
Intervention: Control group from the Border Trial
Number of subjects: 150
Study 22402059 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (ALA) 600 mg/day
Number of subjects: 151
Study 22402059 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (ALA) with and without vitamin E
Number of subjects: 151
Study 22402059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 21109389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) at 3mg/kg per day
Number of subjects: 23
Study 21109389 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza) at 1.5 to 2mg/kg
Number of subjects: 23
Study 20002340 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20 minutes hands-on massage)
Number of subjects: 130
Study 20002340 — intervention group
Group type: COMPARATOR
Intervention: Standard preprocedural care (Control)
Number of subjects: 130
Study 17383643 — intervention group
Group type: EXPERIMENTAL
Intervention: Adept (4% icodextrin solution)
Number of subjects: 402
Study 17383643 — intervention group
Group type: COMPARATOR
Intervention: LRS (lactated Ringer's solution)
Number of subjects: 402
Study 15065980 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive character evidence (CE)
Number of subjects: 0
Study 15065980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-examination
Number of subjects: 0
Study 15065980 — intervention group
Group type: COMPARATOR
Intervention: No character evidence (CE)
Number of subjects: 0
Study 11384630 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/d plus MPA 1.5 mg/d
Number of subjects: 2673
Study 11384630 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/d plus MPA 1.5 mg/d
Number of subjects: 2673
Study 11384630 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/d plus MPA 2.5 mg/d
Number of subjects: 2673
Study 11384630 — intervention group
Group type: COMPARATOR
Intervention: CEE 0.625 mg/d plus MPA 2.5 mg/d
Number of subjects: 2673
Study 9363407 — intervention group
Group type: EXPERIMENTAL
Intervention: INFORMED group (n = 11)
Number of subjects: 22
Study 9363407 — intervention group
Group type: COMPARATOR
Intervention: NON-INFORMED group (n = 11)
Number of subjects: 22
Study 7691119 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (230 micrograms/m2)
Number of subjects: 130
Study 7691119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 7691119 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF
Number of subjects: 130
Study 3768085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 40
Study 3768085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 2645874 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 238
Study 2645874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 31403136 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (BV)
Number of subjects: 60
Study 31403136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28450138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA, anode over F3 and cathode over F4, 20 minutes)
Number of subjects: 20
Study 28450138 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (20 minutes)
Number of subjects: 20
Study 25264109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion assist orthosis (DAO) worn on the weaker leg
Number of subjects: 34
Study 25264109 — intervention group
Group type: COMPARATOR
Intervention: Walking without DAO
Number of subjects: 34
Study 23842013 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive agents in placebo-controlled clinical trials
Number of subjects: 59
Study 21453896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (CPLA)
Number of subjects: 60
Study 21453896 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 60
Study 17874036 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-based closure device (group A) (n=214)
Number of subjects: 366
Study 17874036 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-mediated device (group B) (n=152)
Number of subjects: 366
Study 17874036 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioseal device in PVD patients
Number of subjects: 366
Study 17874036 — intervention group
Group type: EXPERIMENTAL
Intervention: Perclose device in PVD patients
Number of subjects: 366
Study 17073206 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 195
Study 17073206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Bond
Number of subjects: 195
Study 17073206 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Bond
Number of subjects: 195
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available amino acid solution (AA)
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine 25 g
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine 50 g
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine 75 g
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 25 g of lysine plus 25 g of arginine (LysArg)
Number of subjects: 6
Study 12483404 — intervention group
Group type: COMPARATOR
Intervention: Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose)
Number of subjects: 6
Study 12483404 — intervention group
Group type: COMPARATOR
Intervention: No amino acid infusion (controls)
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: LysArg
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine 75 g (Lys75)
Number of subjects: 6
Study 12483404 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic analysis
Number of subjects: 6
Study 10789936 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP via infant flow driver (IFD)
Number of subjects: 36
Study 10789936 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP via single nasal prong
Number of subjects: 36
Study 10789936 — intervention group
Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 36
Study 9561594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (loading dose of 160 mg, followed by 80 mg daily for another 6 doses)
Number of subjects: 102
Study 9561594 — intervention group
Group type: COMPARATOR
Intervention: Quinine (intravenous infusion of loading dose of 20 mg/kg, followed by 10 mg/kg q 8 hourly for 7 days)
Number of subjects: 102
Study 1555463 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 21
Study 1555463 — intervention group
Group type: EXPERIMENTAL
Intervention: spirapril
Number of subjects: 21
Study 3886401 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg single dose
Number of subjects: 0
Study 3886401 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg three times daily for one week
Number of subjects: 0
Study 3886401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg daily for one week
Number of subjects: 0
Study 3886401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29490621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2640 I.E. vitamin D3 q.d. for 28 days)
Number of subjects: 200
Study 29490621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27488750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 49
Study 25000149 — intervention group
Group type: EXPERIMENTAL
Intervention: Candle burning (CB)
Number of subjects: 55
Study 25000149 — intervention group
Group type: EXPERIMENTAL
Intervention: Frying sausages (FS)
Number of subjects: 55
Study 25000149 — intervention group
Group type: EXPERIMENTAL
Intervention: Toasting bread (TB)
Number of subjects: 55
Study 25000149 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 55
Study 22787177 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 287
Study 22787177 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (GL)
Number of subjects: 287
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV6-RUNX1
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: High hyperdiploidy
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrachromosomal amplification of chromosome 21 (iAMP21)
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: t(9;22)
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL translocations
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal 17p
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of 13q
Number of subjects: 1725
Study 20409752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic risk groups (good, intermediate, poor)
Number of subjects: 1725
Study 19258967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block
Number of subjects: 80
Study 19258967 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique
Number of subjects: 80
Study 15729085 — intervention group
Group type: EXPERIMENTAL
Intervention: N-PEP-12
Number of subjects: 54
Study 15729085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11597535 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic urethrocystoscopy
Number of subjects: 100
Study 9532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 800 mL saline at 15 mL per minute, followed by a maintenance infusion at 3 mL per minute
Number of subjects: 326
Study 9532991 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine care
Number of subjects: 326
Study 9532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 800 mL saline
Number of subjects: 326
Study 8127419 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8
Study 8127419 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 8
Study 8127419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 8
Study 8127419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus SF68 (one capsule twice daily for prevention; three times daily for treatment)
Number of subjects: 123
Study 2676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus SF68 (three times daily for treatment)
Number of subjects: 123
Study 2676650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 1092130 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 11
Study 1092130 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11
Study 31340116 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 305
Study 31340116 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 305
Study 29067756 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)–based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide)
Number of subjects: 5888
Study 29067756 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan monotherapy
Number of subjects: 5888
Study 27318919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at 0.5 μg/kg before induction and 0.2 μg/(kg×h) intraoperatively
Number of subjects: 60
Study 27318919 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 25073269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DM)
Number of subjects: 100
Study 25073269 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study 25073269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 100
Study 22822562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with feedback benchmarked against other centers (benchmarking group)
Number of subjects: 0
Study 22822562 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 19583073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 40 mg/kg
Number of subjects: 104
Study 19583073 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 104
Study 17524249 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive PTB+ patients
Number of subjects: 655
Study 17524249 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative PTB+ patients
Number of subjects: 655
Study 17524249 — intervention group
Group type: EXPERIMENTAL
Intervention: PTB+ patients
Number of subjects: 655
Study 15158293 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (25 and 20 kcal/kg for women <60 and >=60 years; 30 and 25 kcal/kg for men <60 and >=60 years)
Number of subjects: 494
Study 15158293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (5 kcal/kg higher than group 1)
Number of subjects: 494
Study 15158293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 494
Study 12228083 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based curriculum on herbs and dietary supplements (10 weeks, 20 case-based modules)
Number of subjects: 537
Study 12228083 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 537
Study 12228083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after completing the curriculum
Number of subjects: 537
Study 9694050 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified nucleohistone-binding antibodies from anti-DNA-depleted plasma IgG
Number of subjects: 2
Study 9694050 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified antibodies from nephritis patient
Number of subjects: 2
Study 9694050 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorption of purified antibodies with histone
Number of subjects: 2
Study 8137684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 9
Study 8137684 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study 2551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with home care coordination by a nurse
Number of subjects: 273
Study 2551083 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual procedures
Number of subjects: 273
Study 2551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 273
Study 2551083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273
Study 2551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 273
Study 1132916 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 39
Study 1132916 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 39
Study 1132916 — intervention group
Group type: COMPARATOR
Intervention: Control (Practice only)
Number of subjects: 39
Study 31638969 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential education group
Number of subjects: 101
Study 31638969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 28731778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment algorithm
Number of subjects: 40
Study 28731778 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one psychiatric medication
Number of subjects: 40
Study 25278336 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 148
Study 25278336 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and shortwave therapy)
Number of subjects: 148
Study 24022337 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI subjects
Number of subjects: 153
Study 24022337 — intervention group
Group type: COMPARATOR
Intervention: Previous personality traits
Number of subjects: 153
Study 24022337 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 153
Study 22352972 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders not otherwise specified (EDNOS) in males and females
Number of subjects: 641
Study 22352972 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy weight control methods
Number of subjects: 641
Study 19390751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg riboflavin daily for 28 days
Number of subjects: 42
Study 19390751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17356099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218
Study 17356099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) in patients with upper-lobe emphysema and low exercise capacity
Number of subjects: 1218
Study 17356099 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1218
Study 15120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stearidonic acid (1g/day) and gamma-linolenic acid (0.9g/day)
Number of subjects: 8